Canada markets closed

Nuvo Pharmaceuticals Inc. (MRVFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.2000-0.0200 (-1.64%)
At close: 03:39PM EST

Nuvo Pharmaceuticals Inc.

6733 Mississauga Road
Suite 800
Mississauga, ON L5N 6J5
905 673 6980

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees101

Key Executives

NameTitlePayExercisedYear Born
Mr. Jesse F. LedgerPres & CEO421.28kN/AN/A
Ms. Mary-Jane E. Burkett C.A., CPA, HBAVP & CFO82.86kN/AN/A
Dr. Bernard Joseph Chiasson Ph.D.VP of Operations & Chief Scientific Officer351.81kN/AN/A
Ms. Katina K. Loucaides M.Sc., LL.BVP, Corp. Sec. & Gen. Counsel349.97kN/AN/A
Ms. Kelly Demerino C.A., CPASr. Director of Fin. & Corp. Controller214.28kN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nuvo Pharmaceuticals Inc. provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet migraine medicine; NeoVisc viscosupplement for knee osteoarthritis; and Resultz/FullMarks/LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Viskazide and Visken antihypertensive agents; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; Uracyst for mild to severe GAG layer damage of the urinary bladder; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA/RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

Corporate Governance

Nuvo Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.